Clinical trials: High-Risk Cancer, open to volunteers
Breast Cancer, Prostate Cancer
Researching the Effect of Exercise on Cancer
Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs…
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer, Stage I Breast Cancer
- Trial name
- NCT04589468
- Testing
- Exercise
- Where
- 9 sites in United States
- Volunteers
- 51 people
- Sponsor
- City of Hope Medical Center
HER2 Negative Breast Cancer
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
This is a Phase II, two-arm, single center, patient preference study designed to evaluate the impact of omitting adjuvant chemotherapy in moderate to high-anatomical risk, low-genomic risk (men or premenopausal women T2-3N0 and…
- Trial name
- SELECT (NCT06953882)
- Testing
- Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Yale University
Breast Cancer
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
The study is being conducted to evaluate the efficacy and safety of HRS-8080 in patients with intermediate or high risk early breast cancer.
- Trial name
- NCT07349069
- Testing
- HRS-8080 Tablets, Letrozole tablets, Tamoxifen Citrate Tablets
- Where
- 2 sites in China
- Volunteers
- 5,500 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Malignant Melanoma
Modified Vaccine for High Risk or Low Residual Melanoma Patients
This study is designed for patients who had malignant melanoma and, following tumor removal, are now free of disease, or have only very minor residual disease, and are at a very high risk of disease recurrence.
- Trial name
- NCT01898039
- Testing
- A2/4-1BBL melanoma vaccine, DNP sensititzation, Cyclophosphamide
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Glioblastoma, High-Grade Glioma (WHO III-IV)
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)
Brain tumors account for 1.35% of all cancers and cause 2.2% of cancer-related deaths. Gliomas are the most common type, comprising 40-90% of central nervous system tumors in different age groups.
- Conditions
- Glioblastoma, High-Grade Glioma (WHO III-IV), Glioblastoma (GBM)
- Trial name
- NCT07488754
- Testing
- Radiation: Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)
- Where
- 2 sites in Poland
- Volunteers
- 35 people
- Sponsor
- Medical University of Warsaw
High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
This is a prospective, randomized, controlled Phase II clinical study designed to evaluate the efficacy and safety of adding Aitua Combination Antibody (a PD-1/CTLA-4 bispecific antibody) to standard neoadjuvant chemotherapy for…
- Conditions
- High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- NCT07432594
- Testing
- Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5)
- Volunteers
- 82 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally Advanced Colon Cancer, pMMR
Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS
Locally advanced colon cancer, particularly T4 disease or colon cancer with bulky nodes, carries a poor prognosis and limited efficacy with neoadjuvant chemotherapy.
- Trial name
- TORCH-C2 (NCT07877597)
- Testing
- short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin)
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Fudan University
Ovarian Cancer, Fallopian Tube Cancer
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
This is an international, multicenter, randomized, open, Phase III trial to evaluate the efficacy and safety of carboplatin/paclitaxel/bevacizumab followed by bevacizumab and niraparib compared to carboplatin/paclitaxel followed…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT05009082
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 65 sites in Germany
- Volunteers
- 970 people
- Sponsor
- AGO Study Group
High Grade Serous Ovarian Cancer
Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma
Background and rationale of the study: From our preliminary analyses of a dataset on patients with high-grade serous ovarian carcinoma (HGSOC), available in the online database The Cancer Genome Atlas, we found that the gene…
- Trial name
- OVCAR (NCT06777082)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity
The CARDIOPROTECT Trial
This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care…
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
- Trial name
- NCT07654426
- Testing
- Dexrazoxane, Doxorubicin, Liposomal Doxorubicin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Beth Israel Deaconess Medical Center
Acute Myeloid Leukemia
Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant
This is a Phase II pilot study to determine the efficacy of three fixed dose (1 x 108/kg) infusions of ex-vivo expanded human leukocyte antigen (HLA)-haploidentical donor natural killer (NK) cells (haploNK) in children and young…
- Trial name
- EXCEL (NCT04836390)
- Testing
- Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- Michael Pulsipher
Non-Small Cell Lung Cancer
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
This is a prospective, single-arm, multi-center, phase II clinical trial to evaluate the efficacy and safety of Chidamide in combination with Ivonescimab in the treatment of advanced non-small cell lung cancer with secondary…
- Trial name
- NSCLC， YAP (NCT07412262)
- Testing
- Chidamide in combination with Ivonescimab
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Guangdong Association of Clinical Trials
Radiotherapy Side Effect, Radiation Toxicity
Curatively Intended Thoracic Reirradiation
The number of long-term lung cancer (LC) survivors increases, however many patients are diagnosed with recurrent or new thoracic cancers. High-dose reirradiation (reRT) is promising but associated with high severe toxicity rates.
- Conditions
- Radiotherapy Side Effect, Radiation Toxicity, Oncology, Lung Cancer
- Trial name
- CureLung (NCT06950073)
- Testing
- Radiotherapy
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- University of Aarhus
High-Risk Localized Prostate Cancer
PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT
This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6…
- Trial name
- NCT07550517
- Testing
- EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Skin Cancers
Defining the Role of Optical Super-high Magnification Dermoscopy in the Diagnosis of Skin Tumors
This is a prospective study aimed at evaluating the diagnostic accuracy (compared to histopathological diagnosis) and clinical utility of optical super-high magnification dermoscopy (OSHMD) in detecting and differentiating skin…
- Trial name
- OSHMD (NCT06908720)
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Ospedale San Raffaele
Uterine Cervical Neoplasms
Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy
Radical hysterectomy and radiation therapy are standard treatments for cervical cancer. However, there are no reported studies on the frequency of side effects and treatment outcomes when hypofractionated radiation therapy and…
- Trial name
- POHIM-P3 (NCT06509724)
- Testing
- Conventional Fractionated IMRT, Hypofractionated IMRT
- Where
- South Korea
- Volunteers
- 248 people
- Sponsor
- Samsung Medical Center
High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
This phase Ib/II trial studies the best dose and side effects of venetoclax and how well it works when given with combination chemotherapy in treating patients with newly diagnosed acute myeloid leukemia or acute myeloid leukemia…
- Conditions
- High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03214562
- Testing
- Cytarabine, Filgrastim, Fludarabine
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
This phase II trial studies how well dexrazoxane hydrochloride works in preventing heart-related side effects of chemotherapy in participants with blood cancers, such as acute myeloid leukemia, myelodysplastic syndrome, chronic…
- Conditions
- Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome
- Trial name
- NCT03589729
- Testing
- Cladribine, Cytarabine, Dexrazoxane Hydrochloride
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Urothelial Carcinoma
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
Urothelial cancers of the bladder and upper urinary tract account for over 200,000 deaths and 600,000 diagnoses annually worldwide.
- Trial name
- UROSCOUT-1 (NCT06310759)
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 3,000 people
- Sponsor
- Tampere University Hospital
Prostate Cancer
Bilateral Versus Unilateral Lymph Node Dissection in High-Risk Prostate Cancer (BALANCE)
BALANCE is a multicenter, prospective, randomized controlled trial enrolling men with unilateral high-risk localized prostate cancer identified by prostate biopsy, multiparametric MRI, and PSMA PET imaging.
- Trial name
- BALANCE (NCT07580196)
- Testing
- Unilateral Extended Pelvic Lymph Node Dissection, Bilateral Extended Pelvic Lymph Node Dissection
- Where
- 14 sites in Italy
- Volunteers
- 820 people
- Sponsor
- University of Turin, Italy
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.